EXPRESSION OF ONCOGENES IN LYMPHOPROLIFERATIVE DISORDERS

淋巴增殖性疾病中癌基因的表达

• 批准号: 3813436
• 负责人: M STETLER-STEVENSON
• 金额: --
• 依托单位: DIVISION OF CANCER BIOLOGY AND DIAGNOSIS
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3813436
• 关键词: B lymphocyte; Hodgkin's disease; chimeric proteins; chromosome aberrations; chromosome translocation; fusion gene; gene expression; genetic manipulation; genetic markers; genetic regulation; genetic transcription; human tissue; immunoglobulin genes; lymphoma; natural gene amplification; neoplasm /cancer genetics; nucleic acid probes; oncogenes; prognosis; tissue /cell culture

We have continued in our studies of the expression of bcl-2 in follicular lymphoma and Hodgkin's disease. We developed a procedure for isolation of RNA followed by reverse transcription and PCR amplification. Using this procedure, we are able to measure the levels of expression of bcl-2 in biopsy specimens. In a small series of follicular lymphoma cases, we have found the levels of expression to have a strong correlation with prognosis; however, a greater number of cases must be studied before final conclusions can be drawn. Studies indicate that bcl-2 may incur a growth advantage to cells but that involvement of other oncogenes, especially myc, is necessary to attain full malignant potential. We thus are undertaking a study of levels of expression of myc m-RNA in these same follicular lymphoma specimens using a technique we have developed. As point mutations leading to a protein of increased activity may be as important as levels of RNA, we are also looking for mutations in the myc gene in tumor specimens. This will provide important information as to the interrelationship of various oncogenes in the development of follicular lymphoma. We have demonstrated the t(14;18) translocation to be present in 32% of Hodgkin's lymphomas. However, Hodgkin's disease and follicular lymphoma are two distinct clinical-pathological entities. We shall also examine the expression of the bcl-2/JH transcript and of the bcl-2 protein product in Hodgkin's disease patients and again correlate this information with the clinical course. This data will provide further information concerning the role of bcl-2 in hematopoietic malignancies.

我们继续研究bcl2在卵泡中的表达。 淋巴瘤和霍奇金氏病。我们开发了一种分离程序来分离 RNA经逆转录、聚合酶链式反应扩增。使用这个 程序中，我们能够测量bcl2的表达水平 活组织检查样本。在一小系列滤泡性淋巴瘤病例中，我们有 发现其表达水平与预后密切相关； 然而，在得出最终结论之前，必须对更多的案例进行研究 都可以被画出来。研究表明，bcl-2可能会导致生长优势 但其他癌基因，特别是myc的参与是必要的 以充分发挥其恶性潜能。因此，我们正在进行一项研究 这些滤泡性淋巴瘤中myc m-RNA的表达水平 使用我们开发的一种技术来获取标本。由于点突变导致 对于一种活性增加的蛋白质来说，可能与RNA水平一样重要，我们 他们还在寻找肿瘤标本中myc基因的突变。这 将提供关于不同类型的 癌基因在滤泡性淋巴瘤发生中的作用 我们已经证明t(14；18)易位存在于32%的 霍奇金淋巴瘤。然而，霍奇金氏病和滤泡性淋巴瘤 两个截然不同的临床病理实体。我们还将研究 BCL-2/JH转录本及其蛋白产物在大肠埃希菌中的表达 霍奇金氏病患者，并再次将此信息与 临床课程。这些数据将提供有关 Bcl2在血液系统恶性肿瘤中的作用